Structure Therapeutics Inc ADR GPCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $28.98
- Day Range
- $27.57–29.25
- 52-Week Range
- $25.59–94.90
- Bid/Ask
- $27.70 / $28.15
- Shares Outstanding
- 71.31M
- Market Cap
- $1.97B
- Volume/Avg
- 2M / 915,093
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 281
- Website
- https://www.structuretx.com
Valuation
|
Metric
|
GPCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GPCR
|
|---|---|
Quick Ratio | 20.31 |
Current Ratio | 20.75 |
Interest Coverage | — |
Quick Ratio
GPCR
Profitability
|
Metric
|
GPCR
|
|---|---|
Return on Assets (Normalized) | −15.02% |
Return on Equity (Normalized) | −15.81% |
Return on Invested Capital (Normalized) | −19.42% |
Return on Assets
GPCR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<!T$ZS | LOCK|#<bl | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%!%^l? | LOCK|t%dg< | $76B | |||
| Moderna Inc
MRNA
| LOCK|vP@YD$ | LOCK|^z | $75B | |||
| argenx SE ADR
ARGX
| LOCK|@Z%@@^ | LOCK|#&P | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|NzBLQ< | LOCK|T<! | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%@%XjR | LOCK|j?s? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Q?ft>qVj | LOCK|R#FD@ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|^w&%Pvs | LOCK|wn | $24B | |||
| Incyte Corp
INCY
| LOCK|Vq!#B%c | LOCK|cl | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|kwXbmv | LOCK|D?Y | $15B |
United States